BACE1 gene variants do not influence BACE1 activity, levels of APP or A isoforms in CSF in Alzheimer's disease

Molecular Neurodegeneration

Volumn 5, Issue 1, 2010, Pages

  Sjölander, Annica ^a   Zetterberg, Henrik ^a   Andreasson, Ulf ^a   Minthon, Lennart ^b,c   Blennow, Kaj ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; DISEASE MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NERVE FIBER DEGENERATION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77957738028     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-5-37     Document Type: Article

References (18)

1. Identification of a novel aspartic protease (Asp 2) as beta-secretase. I Hussain D Powell DR Howlett DG Tew TD Meek C Chapman IS Gloger KE Murphy CD Southan DM Ryan, et al. Mol Cell Neurosci 1999 14 419 427 10.1006/mcne.1999.0811 10656250
2. Purification and cloning of amyloid precursor protein beta-secretase from human brain. S Sinha JP Anderson R Barbour GS Basi R Caccavello D Davis M Doan HF Dovey N Frigon J Hong, et al. Nature 1999 402 537 540 10.1038/990114 10591214
3. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. R Vassar BD Bennett S Babu-Khan S Kahn EA Mendiaz P Denis DB Teplow S Ross P Amarante R Loeloff, et al. Science 1999 286 735 741 10.1126/science.286.5440.735 10531052
4. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. R Yan MJ Bienkowski ME Shuck H Miao MC Tory AM Pauley JR Brashier NC Stratman WR Mathews AE Buhl, et al. Nature 1999 402 533 537 10.1038/990107 10591213
5. Association studies using novel polymorphisms in BACE1 and BACE2. P Nowotny JM Kwon S Chakraverty V Nowotny JC Morris AM Goate, Neuroreport 2001 12 1799 1802 10.1097/00001756-200107030-00008 11435901
6. Polymorphism in the BACE gene influences the risk for Alzheimer's disease. CM Kirschling H Kolsch C Frahnert ML Rao W Maier R Heun, Neuroreport 2003 14 1243 1246 10.1097/00001756-200307010-00011 12824768
7. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. H Zetterberg U Andreasson O Hansson G Wu S Sankaranarayanan ME Andersson P Buchhave E Londos RM Umek L Minthon, et al. Arch Neurol 2008 65 1102 1107 10.1001/archneur.65.8.1102 18695061
8. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Z Zhong M Ewers S Teipel K Burger A Wallin K Blennow P He C McAllister H Hampel Y Shen, Arch Gen Psychiatry 2007 64 718 726 10.1001/archpsyc.64.6.718 17548753
9. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan, Neurology 1984 34 939 944 6610841
10. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. G Wu S Sankaranarayanan K Tugusheva J Kahana G Seabrook XP Shi E King V Devanarayan JJ Cook AJ Simon, Clin Biochem 2008 41 986 996 10.1016/j.clinbiochem.2008.04.022 18489907
11. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? K Blennow A Wallin H Agren C Spenger J Siegfried E Vanmechelen, Mol Chem Neuropathol 1995 26 231 245 10.1007/BF02815140 8748926
12. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. H Vanderstichele E Van Kerschaver C Hesse P Davidsson MA Buyse N Andreasen L Minthon A Wallin K Blennow E Vanmechelen, Amyloid 2000 7 245 258 10.3109/13506120009146438 11132093
13. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. JA Prince L Feuk WM Howell M Jobs T Emahazion K Blennow AJ Brookes, Genome Res 2001 11 152 162 10.1101/gr.150201 11156624
14. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. K Blennow A Ricksten JA Prince AJ Brookes T Emahazion C Wasslavik N Bogdanovic N Andreasen S Batsman J Marcusson, et al. J Neural Transm 2000 107 1065 1079 10.1007/s007020070052 11041282
15. The HUGO Gene Nomenclature Database, 2006 updates. TA Eyre F Ducluzeau TP Sneddon S Povey EA Bruford MJ Lush, Nucleic Acids Res 2006 34 319 321 10.1093/nar/gkj147 16381876
16. Results of a high-resolution genome screen of 437 Alzheimer's disease families. D Blacker L Bertram AJ Saunders TJ Moscarillo MS Albert H Wiener RT Perry JS Collins LE Harrell RC Go, et al. Hum Mol Genet 2003 12 23 32 10.1093/hmg/ddg007 12490529
17. The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease. T Murphy A Yip C Brayne D Easton JG Evans J Xuereb N Cairns MM Esiri DC Rubinsztein, Neuroreport 2001 12 631 634 10.1097/00001756- 200103050-00040 11234778
18. Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1. J Clarimon J Bertranpetit F Calafell M Boada L Tarraga D Comas, J Neurol 2003 250 956 961 10.1007/s00415-003-1127-8 12928915